140 related articles for article (PubMed ID: 38133593)
1. Vonoprazan (Voquezna) for erosive esophagitis.
Med Lett Drugs Ther; 2023 Dec; 65(1692):203-205. PubMed ID: 38133593
[No Abstract] [Full Text] [Related]
2. Two vonoprazan combinations (Voquezna) for H. pylori.
Med Lett Drugs Ther; 2022 Oct; 64(1662):169-172. PubMed ID: 36383768
[No Abstract] [Full Text] [Related]
3. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
4. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis.
Yang S; Deng W; Xie Z; Chen J
Medicine (Baltimore); 2022 Nov; 101(47):e31807. PubMed ID: 36451489
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
Simadibrata DM; Lesmana E; Fass R
J Gastroenterol Hepatol; 2024 Jun; 39(6):988-999. PubMed ID: 38353152
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
[TBL] [Abstract][Full Text] [Related]
9. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis.
Bandyopadhyay S; Verma P; Samajdar SS; Das S
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102373. PubMed ID: 38719148
[TBL] [Abstract][Full Text] [Related]
11. Comparison tables: H2-receptor antagonists and PPIs.
Med Lett Drugs Ther; 2022 Apr; 64(1647):e56-e57. PubMed ID: 35348553
[No Abstract] [Full Text] [Related]
12. Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Ishii M; Kawai T; Tsujita K; Igarashi A; Suzuki M; Deguchi H; Fernandez J
Circ J; 2023 Jan; 87(2):348-359. PubMed ID: 36002313
[TBL] [Abstract][Full Text] [Related]
13. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
Raghunath AS; Green JR; Edwards SJ
Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
[TBL] [Abstract][Full Text] [Related]
14. A study for every second day administration of vonoprazan for maintenance treatment of erosive GERD (ESD von GERD): a multicenter randomized cross-over study.
Matsuda S; Kato M; Sakakibara Y; Hamada H; Sasaki Y; Mori H; Hirai Y; Inoue S; Toyokawa T; Kagaya T; Kuwai T; Esaka N; Yamashita H; Watanabe N; Matsumoto M; Fujii H; Demura M; Kubo K; Mabe K; Harada N
J Gastroenterol; 2022 Mar; 57(3):133-143. PubMed ID: 35092498
[TBL] [Abstract][Full Text] [Related]
15. Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study.
Kambara H; Hosohata K; Nakatsuji T; Ueno S; Oyama S; Inada A; Niinomi I; Wakabayashi T; Iwanaga K
Pharmazie; 2020 Oct; 75(10):527-530. PubMed ID: 33305731
[TBL] [Abstract][Full Text] [Related]
16. Network Meta-analysis Comparing Vonoprazan and Proton Pump Inhibitors for Heartburn Symptoms in Erosive Esophagitis.
Oshima T; Igarashi A; Nakano H; Deguchi H; Fujimori I; Fernandez J
J Clin Gastroenterol; 2022 Jul; 56(6):493-504. PubMed ID: 35470298
[TBL] [Abstract][Full Text] [Related]
17. Does the Novel Potassium-Competitive Acid Blocker Vonoprazan Cause More Hypergastrinemia than Conventional Proton Pump Inhibitors? A Multicenter Prospective Cross-Sectional Study.
Kojima Y; Takeuchi T; Sanomura M; Higashino K; Kojima K; Fukumoto K; Takata K; Sakamoto H; Sakaguchi M; Tominaga K; Higuchi K
Digestion; 2018; 97(1):70-75. PubMed ID: 29393198
[TBL] [Abstract][Full Text] [Related]
18. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
19. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.
Watanabe K; Shimodaira Y; Takahashi S; Fukuda S; Koizumi S; Matsuhashi T; Iijima K
Am J Gastroenterol; 2021 Aug; 116(8):1632-1637. PubMed ID: 33989224
[TBL] [Abstract][Full Text] [Related]
20. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
